You are here: Home » Companies » News
Business Standard

Cadila shares extend gains; surge nearly 5%

USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms

Press Trust of India  |  New Delhi 

Cadila shares extend gains; surge nearly 5%

Healthcare surged nearly 5 per cent on Friday, extending its gains for the second session, after the company said the US Food and Drug Administration (USFDA) has inspected its Moraiya plant and found the unit complying with manufacturing norms.

The stock gained 4.27 per cent to end at Rs 447.80 on During the day, it surged 7.11 per cent to Rs 460 — its 52-week high.

On NSE, of the company jumped 4.78 per cent to close at Rs 450.05.

On the volume front, 12.36 lakh of the company were traded on and over one crore changed hands at during the day.

The stock had surged 20 per cent in the previous session as well, adding Rs 9,188.19 crore to Rs 45,843.19 in its market valuation.

"USFDA inspected company's Moraiya facility from February 6, 2017, to February 15, 2017. At the end of the inspection no observation (483) is issued," Healthcare said in a filing to on Thursday.

The FDA Form 483 notifies the company's management of objectionable conditions.

As per the US health regulator's website, "An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts."

RECOMMENDED FOR YOU

Cadila shares extend gains; surge nearly 5%

USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms

USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms
Healthcare surged nearly 5 per cent on Friday, extending its gains for the second session, after the company said the US Food and Drug Administration (USFDA) has inspected its Moraiya plant and found the unit complying with manufacturing norms.

The stock gained 4.27 per cent to end at Rs 447.80 on During the day, it surged 7.11 per cent to Rs 460 — its 52-week high.

On NSE, of the company jumped 4.78 per cent to close at Rs 450.05.

On the volume front, 12.36 lakh of the company were traded on and over one crore changed hands at during the day.

The stock had surged 20 per cent in the previous session as well, adding Rs 9,188.19 crore to Rs 45,843.19 in its market valuation.

"USFDA inspected company's Moraiya facility from February 6, 2017, to February 15, 2017. At the end of the inspection no observation (483) is issued," Healthcare said in a filing to on Thursday.

The FDA Form 483 notifies the company's management of objectionable conditions.

As per the US health regulator's website, "An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts."
image
Business Standard
177 22

Cadila shares extend gains; surge nearly 5%

USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms

Healthcare surged nearly 5 per cent on Friday, extending its gains for the second session, after the company said the US Food and Drug Administration (USFDA) has inspected its Moraiya plant and found the unit complying with manufacturing norms.

The stock gained 4.27 per cent to end at Rs 447.80 on During the day, it surged 7.11 per cent to Rs 460 — its 52-week high.

On NSE, of the company jumped 4.78 per cent to close at Rs 450.05.

On the volume front, 12.36 lakh of the company were traded on and over one crore changed hands at during the day.

The stock had surged 20 per cent in the previous session as well, adding Rs 9,188.19 crore to Rs 45,843.19 in its market valuation.

"USFDA inspected company's Moraiya facility from February 6, 2017, to February 15, 2017. At the end of the inspection no observation (483) is issued," Healthcare said in a filing to on Thursday.

The FDA Form 483 notifies the company's management of objectionable conditions.

As per the US health regulator's website, "An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts."

image
Business Standard
177 22